IL112674A - Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan - Google Patents

Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan

Info

Publication number
IL112674A
IL112674A IL11267495A IL11267495A IL112674A IL 112674 A IL112674 A IL 112674A IL 11267495 A IL11267495 A IL 11267495A IL 11267495 A IL11267495 A IL 11267495A IL 112674 A IL112674 A IL 112674A
Authority
IL
Israel
Prior art keywords
liquid aqueous
aqueous ophthalmic
sustained release
pharmaceutical composition
ophthalmic
Prior art date
Application number
IL11267495A
Other versions
IL112674A0 (en
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of IL112674A0 publication Critical patent/IL112674A0/en
Publication of IL112674A publication Critical patent/IL112674A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Infusion, Injection, And Reservoir Apparatuses (AREA)
  • Medical Preparation Storing Or Oral Administration Devices (AREA)

Abstract

Disclosed is a sustained release liquid aqueous ophthalmic delivery system and a method of providing a slow and sustained release of ophthalmic treating agents to the eye of a mammal which comprises administering to the eye of a said mammal an effective amount of a homogeneous liquid aqueous ophthalmic pharmaceutical composition, of pH between about 3.0 and about 6.2, which is adminstrable in drop form and which comprises an ophthalmically effective concentration of a said ophthalmic treating agent and about 0.05% to about 10% by weight of the polymer chitosan; said polymer consisting essentially of (A) monomeric beta (1->4)-D-glucosamine linked units and of (B) monomeric beta (1->4)-D-glucosamine linked units which are scattered randomly in the molecule of the polymer, the numerical proportions of A and B being from about 60 to about 99% of A and about 1 to about 40% of B, the viscosity rating being from about 3 to about 3000 cps; in which method, upon contact with the higher pH of the ocular fluid, said liquid formulation is converted to a stiff gel from which the ophthalmic treating agent is slowly released over a prolonged period of time.
IL11267495A 1994-02-18 1995-02-16 Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan IL112674A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/198,924 US5422116A (en) 1994-02-18 1994-02-18 Liquid ophthalmic sustained release delivery system

Publications (2)

Publication Number Publication Date
IL112674A0 IL112674A0 (en) 1995-05-26
IL112674A true IL112674A (en) 1999-12-22

Family

ID=22735469

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11267495A IL112674A (en) 1994-02-18 1995-02-16 Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan

Country Status (21)

Country Link
US (1) US5422116A (en)
EP (1) EP0744938B1 (en)
JP (1) JP3720359B2 (en)
CN (1) CN1138530C (en)
AT (1) ATE205079T1 (en)
AU (1) AU704353B2 (en)
CA (1) CA2181715C (en)
CY (1) CY2314B1 (en)
DE (1) DE69522550T2 (en)
DK (1) DK0744938T3 (en)
ES (1) ES2163495T3 (en)
FI (1) FI117851B (en)
GR (1) GR3036884T3 (en)
IL (1) IL112674A (en)
MX (1) MX9603435A (en)
NO (1) NO313861B1 (en)
NZ (1) NZ278668A (en)
PT (1) PT744938E (en)
TW (1) TW317501B (en)
WO (1) WO1995022315A1 (en)
ZA (1) ZA951323B (en)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5762903A (en) * 1995-03-10 1998-06-09 Korea Atomic Energy Research Institute Radioactive chitosan complex for radiation therapy
ZA964653B (en) * 1995-06-06 1996-12-12 Bayer Ag Non-irritation non-sensitizing non-ototoxic otic anti-bacterial compositions
US5843930A (en) * 1995-06-06 1998-12-01 Bayer Corporation Method of treating otitis with ciprofloxacin-hydrocortisone suspension
TW389694B (en) * 1995-08-17 2000-05-11 Novartis Ag Compositions including o-carboxyalkyl chitosan and methods of use in ophthalmics
WO1997007139A2 (en) * 1995-08-17 1997-02-27 Novartis Ag Stabilized chitin derivative compounds
US5641749A (en) * 1995-11-29 1997-06-24 Amgen Inc. Method for treating retinal ganglion cell injury using glial cell line-derived neurothrophic factor (GDNF) protein product
US5641750A (en) * 1995-11-29 1997-06-24 Amgen Inc. Methods for treating photoreceptors using glial cell line-derived neurotrophic factor (GDNF) protein product
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2212300A1 (en) 1997-08-04 1999-02-04 Abdellatif Chenite In vitro or in vivo gelfying chitosan and therapeutic uses thereof
US6174524B1 (en) 1999-03-26 2001-01-16 Alcon Laboratories, Inc. Gelling ophthalmic compositions containing xanthan gum
US6261547B1 (en) 1998-04-07 2001-07-17 Alcon Manufacturing, Ltd. Gelling ophthalmic compositions containing xanthan gum
US6455583B1 (en) * 1998-05-08 2002-09-24 The University Of Miami Method for treating meibomian gland disease
US7288532B1 (en) * 1998-08-21 2007-10-30 The University Of Maryland Biotechnology Institute Modified chitosan polymers and enzymatic methods for the production thereof
US20040152664A1 (en) * 1998-09-02 2004-08-05 Allergan, Inc. Prednisolone compositions
US6214381B1 (en) 1998-09-08 2001-04-10 Effcon, Inc. Methazolamide composition and method of use
PT1128809E (en) * 1998-11-20 2005-04-29 Medidom Lab AQUOSAL OFTHALMAL FORMULACS COMPRISING CHITOSAN
EP1214056B1 (en) * 1999-09-24 2003-10-29 Alcon Inc. Topical suspension formulations containing ciprofloxacin and dexamethasone
ATE243038T1 (en) 1999-11-01 2003-07-15 Alcon Inc PHARMACEUTICAL COMPOSITIONS CONTAINING A FLUOROCHINOLONE ANTIBIOTIC AND XANTHANG GUM
WO2001036000A1 (en) * 1999-11-15 2001-05-25 Bio Syntech Canada, Inc. Temperature-controlled and ph-dependant self-gelling biopolymeric aqueous solution
KR100371092B1 (en) * 1999-12-09 2003-02-05 주식회사대성미생물연구소 The composition of antibacterial complex for animal
US20030158302A1 (en) * 1999-12-09 2003-08-21 Cyric Chaput Mineral-polymer hybrid composition
AU1848601A (en) * 1999-12-09 2001-06-18 Bio Syntech Canada Inc Mineral-polymer hybrid composition
US6348508B1 (en) * 2000-04-04 2002-02-19 Bausch & Lomb Incorporated Method for treating dry eye
US6716970B2 (en) * 2000-04-21 2004-04-06 Adjuvant Pharmaceuticals, Llc Water soluble, randomly substituted partial N-partial O-acetylated chitosan, preserving compositions containing chitosan, and processes for making thereof
DE60002448T2 (en) * 2000-05-26 2004-03-25 Laboratoire Medidom S.A. Antibacterial aqueous ophthalmic formulations with ofloxacin and chitosan
JP5089006B2 (en) * 2000-06-29 2012-12-05 ピラマル ヘルスケア （カナダ） リミテッド Compositions and methods for repair and regeneration of cartilage and other tissues
DK1305033T3 (en) 2000-07-28 2005-01-31 Alcon Inc Pharmaceutical supplements containing tobramycin and xanthan gum
DE60125973D1 (en) * 2000-11-15 2007-02-22 Biosyntech Canada Inc METHOD FOR RECOVERING A DAMAGED BAND DISC
US6720003B2 (en) 2001-02-16 2004-04-13 Andrx Corporation Serotonin reuptake inhibitor formulations
AR034372A1 (en) * 2001-06-08 2004-02-18 Novartis Ag PHARMACEUTICAL COMPOSITIONS
WO2003002066A2 (en) * 2001-06-27 2003-01-09 Diversa Corporation Glycosylated kinamycins and methods of making and using them
ATA13842001A (en) 2001-08-31 2002-10-15 Mucobiomer Biotechnologische F CHITOSAN-THIO-ALKYL-AMIDINE CONJUGATES AND THEIR COSMETIC AND PHARMACEUTICAL USE
ES2353116T3 (en) * 2002-07-16 2011-02-25 Bio Syntech Canada Inc. COMPOSITIONS FOR CYCLOMPATIBLE, INJECTABLE, SELF-GRINDING QUITOSANE DISSOLUTIONS TO ENCAPSULATE AND ADMINISTER LIVING CELLS OR BIOLOGICALLY ACTIVE FACTORS.
US20070172821A1 (en) * 2002-08-23 2007-07-26 Li-Qun Wu Assembly of chitosan onto an electrode surface
AU2003275289A1 (en) * 2002-09-26 2004-04-19 University Of Maryland Baltimore County Polysaccharide-based polymers and methods of making the same
US7790010B2 (en) * 2002-12-20 2010-09-07 University Of Maryland, College Park Spatially selective deposition of polysaccharide layer onto patterned template
TW200416046A (en) * 2002-12-23 2004-09-01 Alcon Inc Contact lens care compositions containing chitin derivatives
GB0300531D0 (en) 2003-01-10 2003-02-12 West Pharm Serv Drug Res Ltd Pharmaceutical compositions
AU2004207507B2 (en) * 2003-01-24 2009-11-19 Eyepoint Pharmaceuticals Us, Inc. Sustained release device and method for ocular delivery of carbonic anhydrase inhibitors
US7883615B2 (en) * 2003-02-12 2011-02-08 University Of Maryland, College Park Controlled electrochemical deposition of polysaccharide films and hydrogels, and materials formed therefrom
US20070148192A1 (en) * 2003-02-21 2007-06-28 Laddha Ritu N Stable ophthalmic composition
US20040202687A1 (en) * 2003-04-14 2004-10-14 Babu M.K. Manoj Ciprofloxacin formulations and methods of making and using the same
US6933289B2 (en) 2003-07-01 2005-08-23 Allergan, Inc. Inhibition of irritating side effects associated with use of a topical ophthalmic medication
US7125967B2 (en) * 2003-10-08 2006-10-24 Adjuvant Pharmaceuticals, Llc Water-soluble chitosan having low endotoxin concentration and methods for making and using the same
US20050101582A1 (en) * 2003-11-12 2005-05-12 Allergan, Inc. Compositions and methods for treating a posterior segment of an eye
US7375404B2 (en) * 2003-12-05 2008-05-20 University Of Maryland Biotechnology Institute Fabrication and integration of polymeric bioMEMS
GB0403938D0 (en) * 2004-02-21 2004-03-24 West Pharm Serv Drug Res Ltd Chitosan containing solution
KR101080056B1 (en) * 2004-12-01 2011-11-04 한국원자력연구원 Radioactive Chitosan Complex Having an Improved Stabilized Gelation in Administering Them to the Body and Their Preparation Method
DE602005007319D1 (en) * 2005-02-17 2008-07-17 Jordanian Pharmaceutical Mfg Formulation for continuous drug release containing chitosan
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
US20090149421A1 (en) * 2005-11-04 2009-06-11 Bio Syntech Canada Inc. Gel formation of polyelectrolyte aqueous solutions by thermally induced changes in ionization state
AU2006311577B2 (en) 2005-11-09 2013-02-07 Zalicus Inc. Methods, compositions, and kits for the treatment of medical conditions
US20070154523A1 (en) * 2005-12-30 2007-07-05 Rick Lewis Controlled pupil dilation for diagnostic and treatment of visual anomalies
US7785624B2 (en) * 2006-03-02 2010-08-31 Inspire Pharmaceuticals, Inc. Pharmaceutical latrunculin formulations
ES2329161T3 (en) * 2006-12-18 2009-11-23 Jorge Luis Benozzi OPHTHALMIC COMPOSITIONS OF PARASIMPATIC AND ANTI-INFLAMMATORY STIMULANTS FOR USE IN THE TREATMENT OF PRESBY.
BRPI0807065A2 (en) 2007-01-31 2017-03-21 Allergan Inc new biomaterials for eye drug release and a method for making and using them
EP2134355A4 (en) * 2007-03-02 2012-01-11 Saint Simeon Lda Novel ophthalmic compositions containing human recombinant lysozyme and use thereof for treating eye conditions and as contact lens solutions
EP2207570A2 (en) 2007-09-14 2010-07-21 Nitto Denko Corporation Drug carriers
CN101780105B (en) * 2009-01-20 2011-09-28 沈阳兴齐制药有限公司 Eye drop of deproteinized calf blood extractive
WO2010135731A1 (en) * 2009-05-22 2010-11-25 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
US8299079B2 (en) 2009-05-22 2012-10-30 Kaufman Herbert E Preparations and methods for ameliorating or reducing presbyopia
WO2011018800A2 (en) 2009-08-13 2011-02-17 Fdc Limited A novel in-situ gel forming solution for ocular drug delivery
DE102010009475B4 (en) 2010-02-26 2011-11-24 F. Holzer Gmbh Process for the preparation of a dosable ready-to-use preparation
US20120231072A1 (en) * 2011-03-11 2012-09-13 Chemisches Institut Schaefer Ag Thermo-responsive hydrogel compositions
CA3049795A1 (en) 2011-09-20 2013-03-28 Juan Carlos Abad Compositions and methods for treating presbyopia, mild hyperopia, and irregular astigmatism
AU2013274582A1 (en) * 2012-06-11 2015-01-22 Macuclear, Inc. Therapeutic formulation and methods of treatment
US10350161B2 (en) * 2013-10-15 2019-07-16 Pharmathen S.A. Preservative free pharmaceutical compositions for ophthalmic administration
TWI609701B (en) 2016-01-05 2018-01-01 國立交通大學 Compound prescription colloidal eyedrop gel and methods of making the same
WO2018033792A2 (en) 2016-08-19 2018-02-22 Orasis Pharmaceuticals Ltd. Ophthalmic pharmaceutical compositions and uses relating thereto
CN106511268A (en) * 2017-01-22 2017-03-22 吉林省始祖生物波医学研究院有限公司 Solution for treating eye diseases and application thereof as well as eye pad and manufacturing method thereof
US9980946B1 (en) 2017-01-25 2018-05-29 Effcon Laboratories, Inc. Extended release methazolamide formulation
KR102472773B1 (en) * 2018-02-28 2022-11-30 산텐 세이야꾸 가부시키가이샤 Ophthalmic composition containing diquafosol and a cationic polymer
WO2019193513A1 (en) * 2018-04-03 2019-10-10 Hyderabad Eye Research Foundation Mucoadhesive drug delivery system for ocular administration of fluoroquinolone antibiotics
HRP20220762T1 (en) 2018-04-24 2022-09-16 Allergan, Inc. Use of pilocarpine hydrochloride for the treatment of presbyopia
US11344507B2 (en) 2019-01-08 2022-05-31 Alumend, Llc Topical compositions containing low molecular weight chitosan derivatives
IT201900006104A1 (en) * 2019-04-18 2020-10-18 S I I T S R L Servizio Int Imballaggi Termosaldanti Method of preparing a chitosan-based product
CN111848835B (en) * 2019-04-30 2023-02-03 苏州大学 Application of fluorine-containing compound modified chitosan in preparation of transdermal drug delivery preparation
KR102656181B1 (en) * 2019-08-27 2024-04-08 산텐 세이야꾸 가부시키가이샤 Aqueous ophthalmic composition containing diquafosol or its salt and polyvinylpyrrolidone
CN114073670B (en) * 2020-08-11 2023-02-24 武汉科福新药有限责任公司 Timolol maleate gel eye drops and preparation method thereof
EP4284362A4 (en) 2021-01-28 2024-12-25 Glaukos Corporation FORMULATIONS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4136173A (en) * 1977-01-31 1979-01-23 American Home Products Corp. Mixed xanthan gum and locust beam gum therapeutic compositions
US4659700A (en) * 1984-03-02 1987-04-21 Johnson & Johnson Products, Inc. Chitosan-glycerol-water gel
AU604236B2 (en) * 1986-04-28 1990-12-13 Iolab, Inc. Intraocular dosage compositions and method of use
IT1190347B (en) * 1986-06-16 1988-02-16 Franco Conti PROCESS FOR THE PREPARATION OF N-DIMETYLCHITOSANE AND ITS PHARMACOLOGICAL USES
JPS6471822A (en) * 1987-09-12 1989-03-16 Rohto Pharma Ophthalmic sustained release preparation
IE63392B1 (en) * 1988-02-08 1995-04-19 Insite Vision Inc Ophthalmic suspensions
FR2653021A1 (en) * 1989-10-17 1991-04-19 Merck Sharp & Dohme AQUEOUS LIQUID OPHTHALMIC COMPOSITION WITH LIQUID-GEL PHASE TRANSITION.
JPH0418022A (en) * 1990-05-10 1992-01-22 Fujikawa Kk Stable aqueous solution of piroxicam and production thereof
JP2536806B2 (en) * 1991-03-27 1996-09-25 アルコン ラボラトリーズ インコーポレイテッド Topical ophthalmic composition combining gelled polysaccharide and finely divided drug carrier
US5318780A (en) * 1991-10-30 1994-06-07 Mediventures Inc. Medical uses of in situ formed gels

Also Published As

Publication number Publication date
CN1140988A (en) 1997-01-22
AU704353B2 (en) 1999-04-22
EP0744938B1 (en) 2001-09-05
EP0744938A1 (en) 1996-12-04
FI963217A7 (en) 1996-08-16
ZA951323B (en) 1995-08-18
AU1464995A (en) 1995-09-04
JPH09509166A (en) 1997-09-16
ATE205079T1 (en) 2001-09-15
CY2314B1 (en) 2003-11-14
NO963431L (en) 1996-10-09
DK0744938T3 (en) 2001-12-31
CN1138530C (en) 2004-02-18
FI117851B (en) 2007-03-30
US5422116A (en) 1995-06-06
NO963431D0 (en) 1996-08-16
GR3036884T3 (en) 2002-01-31
DE69522550T2 (en) 2002-05-02
TW317501B (en) 1997-10-11
PT744938E (en) 2001-12-28
FI963217A0 (en) 1996-08-16
WO1995022315A1 (en) 1995-08-24
NO313861B1 (en) 2002-12-16
IL112674A0 (en) 1995-05-26
MX9603435A (en) 1997-03-29
NZ278668A (en) 1998-01-26
CA2181715A1 (en) 1995-08-24
ES2163495T3 (en) 2002-02-01
JP3720359B2 (en) 2005-11-24
CA2181715C (en) 2006-05-30
DE69522550D1 (en) 2001-10-11

Similar Documents

Publication Publication Date Title
IL112674A (en) Sustained release liquid aqueous ophthalmic delivery system and liquid aqueous ophthalmic pharmaceutical composition both containing the polymer chitosan
KR100379881B1 (en) Conditioning solutions for hard contact lens care
ATE192332T1 (en) ALKALINE OPHTHALMIC SUSPENSIONS
EP0590655B1 (en) Muco-adhesive polymers
EP0799615B1 (en) Liposome eye drops
US5075104A (en) Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
CA1240929A (en) Chondroitin sulfate/sodium hyaluronate compositions
US5106615A (en) Eyedrops having non-newtonian rheological properties
DE60203691T2 (en) Use of dexpanthenol in contact lens care compositions
ATE204745T1 (en) OPTHALMIC SOLUTIONS THICKENED WITH TAMARIND SEED POLYSACHARIDES
IL114193A (en) Ophthalmic pharmaceutical compositions based on sodium alginate
ES2161874T3 (en) OPHTHALMIC COMPOSITION WITH REDUCED VISCOSITY.
GEP20002231B (en) (54) Composition for Using in Ophthalmologic Surgery and Method for Surgical Treatment of Eye
WO2008001872A1 (en) Ophthalmic composition containing alginic acid or salt thereof
US5645827A (en) Muco-adhesive polymers
DE69432188D1 (en) Synthetic viscose elastic material for physiological applications such as for ophthalmic applications
WO1984004681A1 (en) Ophthalmic solution
JPH08510731A (en) In situ produced gel for therapeutic use
WO1984004680A1 (en) Ophthalmic gel
FR2742336B1 (en) EYE DROPS INTENDED IN PARTICULAR FOR TREATING EYE DRY
EP0888770A1 (en) Compositions comprising cationic polysaccharides and cationic drugs

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed
KB Patent renewed
KB Patent renewed
MM9K Patent not in force due to non-payment of renewal fees